Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients
Marco Capobianco(Ospedale San Luigi Gonzaga), Antonio Bertolotto(Neuroscience Institute), Francesca Sperli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Simona Malucchi(Ospedale San Luigi Gonzaga), Alessia Di Sapio(Neuroscience Institute), Annalisa Rizzo(University of Bari Aldo Moro), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Alessandra Oggero(University of Turin), Angelo Ghezzi
Cited by 11
Related Papers
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
|Journal of Neuroinflammation|2016|896
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Myelin-oligodendrocyte glycoprotein antibody-associated disease
|The Lancet Neurology|2021|518
Evidence of early cortical atrophy in MS
|Neurology|2003|485